This randomized double-blinded placebo-controlled study (n=71) investigated the effects of ayahuasca (23.52mg DMT, 130.2mg harmine, 16.8mg harmaline, 84mg tetrahydroharmine /70kg) on salivary and plasma cortisol levels in patients with depression compared to healthy controls. Ayahuasca restored the corticosteroid insufficiency of depressed patients and increased their cortisol response to that of healthy controls.
Abstract
“Introduction: Major depression is a highly prevalent mood disorder, affecting about 350 million people, and around 30% of the patients are resistant to currently available antidepressant medications. Recent evidence from a randomized placebo-controlled trial supports the rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression. The aim of this study was to explore the effect of ayahuasca on plasma cortisol and awakening salivary cortisol response, in the same group of treatment-resistant patients and in healthy volunteers.
Methods: Subjects received a single dose of ayahuasca or placebo, and both plasma and awakening salivary cortisol response were measured at baseline (before dosing) and 48h after the dosing session.
Results: Baseline assessment (D0) showed blunted awakening salivary cortisol response and hypocortisolemia in patients (DM), both with respect to healthy controls group (C). Salivary cortisol also was measured during dosing session and we observed a large increased for both C and DM that ingested ayahuasca, than placebo groups. After 48h of the dosing session (D2) with ayahuasca, awakening salivary cortisol response (for both sexes) of treated patients became similar to levels detected in controls. This was not observed in patients that ingested placebo. No changes in plasma cortisol were observed after 48 hours of ayahuasca or placebo ingestion for both groups and sexes.
Discussion: Therefore, these findings point to new evidence of modulation of ayahuasca on salivary cortisol levels, as cortisol acts in regulation of distinct physiological pathways, emotional and cognitive processes related to etiology of depression, this modulation could be an important part of the antidepressant effects observed with ayahuasca. Moreover, this study highlights the importance of psychedelics in the treatment of human mental disorders.”
Authors: Ana Cecília de Menezes Galvão, Raíssa Nóbrega de Almeida, Erick Allan dos Santos Silva, Fúlvio Aurélio de Morais Freire, Fernanda Palhano-Fontes, Heloisa Onias, Emerson Arcoverdee, João Paulo Maia-de-Oliveira, Draúlio B Araújo, Bruno Lobão-Soares & Nicole Leite Galvão-Coelho
Summary of A Single Dose Of Ayahuasca Modulates Salivary Cortisol In Treatment-Resistant Depression
Introduction
Major depressive disorder has been closely associated with deregulations of the hypothalamic-pituitary-adrenal (HPA) axis, both at rest and in response to stress. However, there is increasing evidence of hypocortisolism in patients with depression.
Cortisol assessments have served as an important biomarker of treatment response in patients with depression.
Find this paper
A Single Dose Of Ayahuasca Modulates Salivary Cortisol In Treatment-Resistant Depression
https://doi.org/http://dx.doi.org/10.1101/257238
Open Access | Google Scholar | Backup | 🕊
Study details
Compounds studied
Ayahuasca
Topics studied
Depression
Treatment-Resistant Depression
Study characteristics
Placebo-Controlled
Double-Blind
Randomized
Participants
71
Authors
Authors associated with this publication with profiles on Blossom
Fernanda Palhano Xavier de FontesFernanda Palhano Xavier de Fontes is a research engineer at the Brain Institute, UFRN. Her main areas of interest are psychedelics, psychiatry, and neuroimaging techniques such as fMRI and electroencephalography.